Change of Company Auditor
Released
Released
Announcement PDF
ASX Announcement
CHANGE OF COMPANY AUDITOR
Melbourne, Australia – 1 October 2024: Percheron Therapeutics Limited (ASX: PER)
(‘Percheron’ or ‘the Company’), an international biotechnology company focused on the
development of novel therapies for rare diseases, advises that William Buck Audit (Vic)
Pty Ltd (‘William Buck’) has been appointed as the Company’s auditors. The
appointment has been formally approved by the Australian Securities & Investment
Commission and, as part of the transition process, a letter of resignation has been
received from Ernst & Young.
The decision to change auditors was made following a consultation process by the
Board involving a review of the Company’s external audit arrangements in accordance
with the Company’s Corporate Governance Plan and Policies. William Buck was chosen
based on their reputation and industry experience.
In accordance with section 327C of the Corporations Act 2001 (Cth), a resolution will be
tabled at the Company’s 2024 Annual General Meeting to confirm the appointment of
William Buck as the auditor of Percheron.
The Board of Directors would like to take this opportunity to thank Ernst & Young for their
professional service.
~ ENDS ~
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJF] is a publicly listed biotechnology
company focused on the development and commercialization of novel therapies for rare
diseases. The company’s lead program is avicursen (ATL1102), an antisense oligonucleotide
targeting the CD49d receptor. Avicursen is currently the subject of an ongoing international
phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular
Dystrophy (DMD), for which data is expected in December CY2024. The company previously
reported promising results from an exploratory phase IIa study of in the same population and
has been awarded orphan drug designation (ODD) and rare pediatric disease designation
(RPDD) by the US FDA.
For more information, please contact info@PercheronTx.com.
This announcement has been authorised for release to the Australian Securities Exchange
by the Board of Directors.
ME_225015766_1
Percheron Therapeutics Limited
ABN 41 095 060 745
ASX: PER | FSE: AWY | US OTC: ATHJY
Share your feedback
Discover